Antibody-based antiangiogenic and antilymphangiogenic therapies to prevent tumor growth and progression

Area of Science:

• Oncology
• Vascular Biology
• Immunotherapy

Background:

• Tumor angiogenesis and lymphangiogenesis are critical for cancer growth and metastasis.
• Strategies to inhibit these processes are under investigation to halt tumor development.
• Monoclonal antibodies present a specific approach to target tumor vascularization pathways.

Purpose of the Study:

• To review the molecular mechanisms of tumor-driven angiogenesis and lymphangiogenesis.
• To discuss antibody-based therapeutic agents targeting these vascularization processes.
• To explore challenges and future directions in anti-angiogenic and anti-lymphangiogenic therapies.

Main Methods:

• Review of molecular mechanisms of angiogenesis and lymphangiogenesis in cancer.
• Analysis of antibody-based therapeutic strategies targeting VEGF family and VEGFRs.
• Discussion of challenges in vascular targeting therapies, including drug resistance.

Main Results:

• Tumors exploit specific molecular pathways for blood and lymphatic vessel formation.
• Antibody-based therapies targeting VEGF/VEGFRs show potential in preclinical and clinical settings.
• Signaling network redundancy contributes to therapeutic resistance in anti-angiogenic treatments.

Conclusions:

• Targeting tumor vascularization with monoclonal antibodies is a key strategy in cancer therapy.
• Understanding vascular biology is crucial for overcoming drug resistance and improving treatment efficacy.
• Combined and novel targeted therapies hold promise for enhanced therapeutic effects in cancer treatment.